On October 6, 2015 Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) reported that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with recurrent or metastatic castration resistant prostate cancer (IND 209) (Press release, Oncolytics Biotech, OCT 6, 2015, View Source [SID:1234507649]). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen’s University in Kingston, Ontario.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Prostate cancer remains a leading cause of cancer-related death in men," said Dr. Brad Thompson, President and CEO of Oncolytics. "As a result, it is important that we continue to conduct studies with late-stage patients to help improve outcomes for this group."
The study is an open-label, randomized, non-blinded, Phase II clinical study of REOLYSIN given in combination with docetaxel versus docetaxel alone. Approximately 40 response evaluable patients were enrolled in each arm.
The primary objective of the trial is to evaluate the efficacy of REOLYSIN in combination with docetaxel based on the lack of disease progression as measured at 12 weeks. Secondary objectives are to determine circulating tumour cell status at six and 12 weeks and the conversion rate of these cells, prostate-specific antigen (PSA) change rate, objective response rate (in patients with measurable disease at baseline), effect on overall survival, the tolerability and toxicity of the treatment combination, and to explore potential molecular factors predictive of response.
Although accrual is complete, patient follow-up will continue until planned analyses have been conducted.
About Prostate Cancer
Prostate cancer is among the most common cancers diagnosed in men. The Canadian Cancer Society estimates that 24,000 Canadian men will be diagnosed with prostate cancer and that 4,100 Canadian men are expected to die from the disease in 2015. The American Cancer Society estimates that 220,800 new cases of prostate cancer will be diagnosed in the United States and that 27,450 Americans are expected to die from the disease in 2015.